Madrigal Pharmaceuticals (MDGL) Operating Income (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Operating Income for 17 consecutive years, with -$56.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Income fell 19.29% year-over-year to -$56.3 million; the TTM figure through Jun 2026 stood at -$322.6 million (down 4.13% YoY), while the FY2025 annual figure was -$300.1 million, up 39.72% from the prior year.
• Operating Income rose to -$56.3 million in Q2 2026 per MDGL's latest filing, from -$92.7 million in the prior quarter.
• Across five years, Operating Income topped out at -$47.2 million in Q2 2025 and bottomed at -$162.5 million in Q2 2024.
• Historically, Operating Income has averaged -$90.1 million across 5 years, with a median of -$82.9 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Income plunged 94.08% — and 2025, when it surged 70.96%.
• Madrigal Pharmaceuticals' Operating Income stood at -$85.3 million in 2022, then tumbled by 37.37% to -$117.2 million in 2023, then soared by 42.82% to -$67.0 million in 2024, then gained by 11.03% to -$59.6 million in 2025, then grew by 5.54% to -$56.3 million in 2026.
• Business Quant data shows MDGL's Operating Income at -$56.3 million in Q2 2026, -$92.7 million in Q1 2026, and -$59.6 million in Q4 2025.